VivoSeq
Other

Croup

4

Pipeline Programs↗

0

Active Trials↗

2

Companies Involved↗

Croup is an early-stage landscape with 4 programs across 2 companies. The most active players are Paratek Pharmaceuticals Inc, Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. 4 therapies are approved.

Intelligence

Pipeline Metrics

Competitive Density

24/100

Pipeline Velocity

0/100

Mech. Concentration

100/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

P

Paratek Pharmaceuticals Inc

1 program

ApprovedP

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

1 program

Approved

Pipeline

Programs by Phase

Analysis

Trial Status

3

clinical trials

Completed2 · 67%
Unknown status1 · 33%

Clinical Trials

Trial Activity

Community Care for Croup (RCT)
Completed·WWashington University School of Medicine·Phase 4·NCT01042145·87 enrolled
The Effect and Safety of Low Dose Nebulized Epinephrine in Croup
Unknown status·SSeoul National University Hospital·Phase 4·NCT01664507·84 enrolled
Croup Dosing Study
Completed·UUniversity of Manitoba·Phase 3·NCT06272383·50 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)